Drug intelligence / Profile preview

Presponse

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

**Presponse** is a commercial bovine vaccine developed by Boehringer Ingelheim Animal Health for preventing respiratory diseases in cattle. **Presponse SQ** targets pneumonic pasteurellosis by stimulating immunity against **Mannheimia haemolytica** (formerly Pasteurella haemolytica) via bacterial surface antigens and leukotoxoids. **Presponse HM** provides protection against pneumonic pasteurellosis due to **Pasteurella multocida** and respiratory disease from **Mannheimia haemolytica** in cattle 7 months or older. It is often combined in products like **Pyramid/Presponse** for broader coverage including BVD, IBR, BRSV, and PI3.[1][2][3][6][7]

Brand names: PresponsePresponse SQPresponse HM

Beyond the preview

Go deeper on Presponse.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presponse.

Explore the full profile